studies

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2), durvalumab plus tremelimumab vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.80 [0.61; 1.05] 0.80[0.61; 1.05]ARCTIC (DT ; study B ; PDL1<25%), 202010%292NAnot evaluable progression or deaths (PFS)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.77 [0.59; 1.01] 0.77[0.59; 1.01]ARCTIC (DT ; study B ; PDL1<25%), 202010%292NAnot evaluable objective responses (ORR)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 2.43 [1.05; 5.65] 2.43[1.05; 5.65]ARCTIC (DT ; study B ; PDL1<25%), 202010%292NAnot evaluable AE (any grade)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.59 [0.20; 1.69] 0.59[0.20; 1.69]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable AE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.70 [0.43; 1.12] 0.70[0.43; 1.12]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable AE leading to death (grade 5)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 1.41 [0.52; 3.82] 1.41[0.52; 3.82]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable AE leading to treatment discontinuation (any grade)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 1.09 [0.58; 2.03] 1.09[0.58; 2.03]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable SAE (any grade)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 1.76 [1.04; 2.99] 1.76[1.04; 2.99]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable TRAE (any grade)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.39 [0.22; 0.69] 0.39[0.22; 0.69]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.49 [0.29; 0.84] 0.49[0.29; 0.84]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable TRAE leading to death (grade 5)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23] 0.63[0.01; 32.23]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable TRAE leading to discontinuation (any grade)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 1.81 [0.81; 4.05] 1.81[0.81; 4.05]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Acute kidney injury TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28] 1.27[0.04; 38.28]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28] 1.27[0.04; 38.28]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Anaemia TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.21 [0.02; 2.02] 0.21[0.02; 2.02]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Asthenia TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28] 1.27[0.04; 38.28]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 3.86 [0.19; 77.90] 3.86[0.19; 77.90]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.09; 4.55] 0.63[0.09; 4.55]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 3.24 [0.37; 28.15] 3.24[0.37; 28.15]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 2.56 [0.11; 57.33] 2.56[0.11; 57.33]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.47 [0.10; 2.13] 0.47[0.10; 2.13]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 1.92 [0.20; 18.73] 1.92[0.20; 18.73]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Hypersensitivity TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28] 1.27[0.04; 38.28]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Hypertension TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.11; 14.23] 1.27[0.11; 14.23]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23] 0.63[0.01; 32.23]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Hypophysitis TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28] 1.27[0.04; 38.28]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23] 0.63[0.01; 32.23]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Increase AST TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23] 0.63[0.01; 32.23]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.04; 10.24] 0.63[0.04; 10.24]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Increased lipase level TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23] 0.63[0.01; 32.23]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23] 0.63[0.01; 32.23]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.10 [0.01; 2.08] 0.10[0.01; 2.08]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23] 0.63[0.01; 32.23]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Nausea TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23] 0.63[0.01; 32.23]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.03 [0.00; 0.45] 0.03[0.00; 0.45]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Pancreatitis TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 2.56 [0.11; 57.33] 2.56[0.11; 57.33]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Peripheral oedema TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28] 1.27[0.04; 38.28]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Pneumonia TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23] 0.63[0.01; 32.23]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 6.52 [0.35; 120.50] 6.52[0.35; 120.50]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Pruritic rash TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28] 1.27[0.04; 38.28]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Pruritus TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23] 0.63[0.01; 32.23]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.32 [0.01; 9.50] 0.32[0.01; 9.50]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Rash TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.31 [0.03; 3.50] 0.31[0.03; 3.50]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Stomatitis TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28] 1.27[0.04; 38.28]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.16 [0.01; 3.50] 0.16[0.01; 3.50]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.63 [0.01; 32.23] 0.63[0.01; 32.23]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Vomiting TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 0.32 [0.01; 9.50] 0.32[0.01; 9.50]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable Weight decreased TRAE (grade 3-4)detailed resultsARCTIC (DT ; study B ; PDL1<25%), 2020 1.27 [0.04; 38.28] 1.27[0.04; 38.28]ARCTIC (DT ; study B ; PDL1<25%), 202010%283NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-06-14 11:35 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169 - treatments: 634,861

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons